RxSight, Inc. has recently been upgraded to a "Buy" rating by UBS due to their innovative approach to cataract surgery.

The company specializes in improving patients' vision after surgery with their proprietary RxSight Light Adjustable Lens System. This system includes the Light Adjustable Lens (LAL), which can change its shape in response to specific ultraviolet light patterns, and the Light Delivery Device (LDD) used to administer these adjustments. The goal of this technology is to address the limitations of traditional intraocular lens options and provide a reliable solution for better visual outcomes.

Surgeons can still perform standard cataract procedures while using the RxSight system to customize the lens correction for each patient.